@article{6f5c0aec612c4ebcb2a53d28a128b77d,
title = "Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia",
author = "Abhishek Maiti and Jorge Cortes and Alessandra Ferrajoli and Zeev Estrov and Gautam Borthakur and Guillermo Garcia-Manero and Elias Jabbour and Farhad Ravandi and Susan O{\textquoteright}Brien and Hagop Kantarjian",
note = "Funding Information: This original research was sponsored by ChemGenex Pharmaceuticals, Ltd (Menlo Park, CA), which is now a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (Frazer, PA). This study was supported in part by the M.D. Anderson Cancer Center Support Grant CA016672 (PI: Dr Ronald DePinho) from the National Cancer Institute, and the CML P01 Grant P01 CA049639 (PI: Dr Richard Champlin).",
year = "2017",
month = sep,
day = "2",
doi = "10.1080/10428194.2017.1283030",
language = "English (US)",
volume = "58",
pages = "2240--2242",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",
}
